Skip to main content
SpringerLink
Log in

Heart Failure in African Americans and Hispanic Americans: A Persistent and Disproportionate Burden in Underrepresented Minorities

  • Chapter
  • First Online:
Cardiovascular Disease in Racial and Ethnic Minority Populations

Part of the book series: Contemporary Cardiology ((CONCARD))

Abstract

Heart failure (HF) is increasing in prevalence in the United States. African Americans and Hispanic Americans have a disproportionate burden of cardiovascular disease risk factors contributing to a higher prevalence and worse outcomes in HF. In 2011, the American Heart Association outlined the “Life’s Simple 7” metrics created to improve cardiovascular health in the United States by 20% by 2020. These goals are of particularly import for the African American and Hispanic American populations to mitigate the risk of HF and improve outcomes once overt disease is present. In addition, the social determinants of health also play a major role in contributing to the disparities seen in minority groups. While disparities exist, there are a number of successes in treatment and utilization of guideline-directed medical therapies. Clinicians should be aware of the prevalence of heart failure in special populations and factors that contribute to disparities in HF outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ponikowski P, Anker SD, AlHabib KF, et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1(1):4–25. https://doi.org/10.1002/ehf2.12005.

    Article  PubMed  Google Scholar 

  2. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–e492. https://doi.org/10.1161/CIR.0000000000000558.

    Article  PubMed  Google Scholar 

  3. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States. Circ Heart Fail. 2013;6(3):606–19. https://doi.org/10.1161/HHF.0b013e318291329a.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Yancy CW, Jessup M, Bozkurt B, et al. 2 013 ACCF/AHA guideline for the Management of Heart Failure. Circulation. 2013;128(16):e240–327. https://doi.org/10.1161/CIR.0b013e31829e8776.

    Article  PubMed  Google Scholar 

  5. van der Meer P, Gaggin HK, Dec GW. ACC/AHA versus ESC guidelines on heart failure: JACC guideline comparison. J Am Coll Cardiol. 2019;73(21):2756–68. https://doi.org/10.1016/j.jacc.2019.03.478.

    Article  PubMed  Google Scholar 

  6. U.S. Census Bureau QuickFacts: United States. https://www.census.gov/quickfacts/fact/table/US/PST045218. Accessed June 13, 2019.

  7. Taylor A, Wright J. Importance of race/ethnicity in clinical trials: lessons from the African-American heart failure trial (A-HeFT), the African-American study of kidney disease and hypertension (AASK), and the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation. 2005;112(23):3654–60. https://doi.org/10.1161/CIRCULATIONAHA.105.540443.

    Article  PubMed  Google Scholar 

  8. Weinick RM, Jacobs EA, Stone LC, Ortega AN, Burstin H. Hispanic healthcare disparities: challenging the myth of a monolithic Hispanic population. Med Care. 2004;42(4):313. https://doi.org/10.1097/01.mlr.0000118705.27241.7c.

    Article  PubMed  Google Scholar 

  9. Novello AC, Wise PH, Kleinman DV. Hispanic health: time for data, time for action. JAMA. 1991;265(2):253–5. https://doi.org/10.1001/jama.1991.03460020107038.

    Article  CAS  PubMed  Google Scholar 

  10. Vivo RP, Krim SR, Cevik C, Witteles RM. Heart failure in Hispanics. J Am Coll Cardiol. 2009;53(14):1167–75. https://doi.org/10.1016/j.jacc.2008.12.037.

    Article  PubMed  Google Scholar 

  11. LaVeist TA. Beyond dummy variables and sample selection: what health services researchers ought to know about race as a variable. Health Serv Res. 1994;29(1):1–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Williams DR, Jackson JS. Race/ethnicity and the 2000 census: recommendations for African American and other black populations in the United States. Am J Public Health. 2000;90(11):1728–30. https://doi.org/10.2105/ajph.90.11.1728.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Agyemang C, Bhopal R, Bruijnzeels M. Negro, Black, Black African, African Caribbean, African American or what? Labelling African origin populations in the health arena in the 21st century. J Epidemiol Community Health. 2005;59(12):1014–8. https://doi.org/10.1136/jech.2005.035964.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Black/African American – The Office of Minority Health. https://www.minorityhealth.hhs.gov/omh/browse.aspx?lvl=3&lvlid=61. Accessed June 14, 2019.

  15. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397–402. https://doi.org/10.1056/NEJMoa020265.

    Article  PubMed  Google Scholar 

  16. Barker WH, Mullooly JP. Getchell William. Changing incidence and survival for heart failure in a well-defined older population, 1970–1974 and 1990–1994. Circulation. 2006;113(6):799–805. https://doi.org/10.1161/CIRCULATIONAHA.104.492033.

    Article  PubMed  Google Scholar 

  17. Huffman MD, Berry JD, Ning H, et al. Lifetime risk for heart failure among White and Black Americans: cardiovascular lifetime risk pooling project. J Am Coll Cardiol. 2013;61(14):1510–7. https://doi.org/10.1016/j.jacc.2013.01.022.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175(6):996–1004. https://doi.org/10.1001/jamainternmed.2015.0924.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Bahrami H, Kronmal R, Bluemke DA, et al. Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med. 2008;168(19):2138–45. https://doi.org/10.1001/archinte.168.19.2138.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Chang PP, Chambless LE, Shahar E, et al. Incidence and survival of hospitalized acute decompensated heart failure in four US communities (from the atherosclerosis risk in communities study). Am J Cardiol. 2014;113(3):504–10. https://doi.org/10.1016/j.amjcard.2013.10.032.

    Article  PubMed  Google Scholar 

  21. Lloyd-Jones Donald M, Yuling H, Darwin L, et al. Defining and setting National Goals for cardiovascular health promotion and disease reduction. Circulation. 2010;121(4):586–613. https://doi.org/10.1161/CIRCULATIONAHA.109.192703.

    Article  CAS  PubMed  Google Scholar 

  22. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the atherosclerosis risk in communities study). Am J Cardiol. 2008;101(7):1016–22. https://doi.org/10.1016/j.amjcard.2007.11.061.

    Article  PubMed  Google Scholar 

  23. Pandey DK, Labarthe DR, Goff DC, Chan W, Nichaman MZ. Community-wide coronary heart disease mortality in Mexican Americans equals or exceeds that in non-Hispanic whites: the Corpus Christi heart project. Am J Med. 2001;110(2):81–7. https://doi.org/10.1016/S0002-9343(00)00667-7.

    Article  CAS  PubMed  Google Scholar 

  24. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP, Hazuda HP. All-cause and cardiovascular mortality among Mexican-American and non-Hispanic White older participants in the San Antonio heart study— evidence against the “Hispanic paradox.”. Am J Epidemiol. 2003;158(11):1048–57. https://doi.org/10.1093/aje/kwg249.

    Article  PubMed  Google Scholar 

  25. Dunlay SM, Weston SA, Jacobsen SJ, Roger VL. Risk factors for heart failure: a population-based case-control study. Am J Med. 2009;122(11):1023–8. https://doi.org/10.1016/j.amjmed.2009.04.022.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Kalogeropoulos A, Georgiopoulou V, Kritchevsky SB, et al. Epidemiology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composition study. Arch Intern Med. 2009;169(7):708–15. https://doi.org/10.1001/archinternmed.2009.40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Yancy CW. Heart failure in African Americans: a cardiovascular enigma. J Card Fail. 2000;6(3):183–6. https://doi.org/10.1054/jcaf.2000.17610.

    Article  CAS  PubMed  Google Scholar 

  28. Centers for Disease Control and Prevention (CDC). Prevalence of diabetes among Hispanics–selected areas, 1998-2002. MMWR Morb Mortal Wkly Rep. 2004;53(40):941–4.

    Google Scholar 

  29. War d BW. Early Release of Selected Estimates Based on Data From the 2015 National Health Interview Survey (05/2016). 2015:120.

    Google Scholar 

  30. Trends in Obesity Among Adults in the United States, 2005 to 2014 | Obesity | JAMA | JAMA Network. https://jamanetwork-com.ezproxy.galter.northwestern.edu/journals/jama/fullarticle/2526639. Accessed June 17, 2019.

  31. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340(8):609–16. https://doi.org/10.1056/NEJM199902253400804.

    Article  CAS  PubMed  Google Scholar 

  32. Willett WC, Sacks F, Trichopoulou A, et al. Mediterranean diet pyramid: a cultural model for healthy eating. Am J Clin Nutr. 1995;61(6):1402S–6S. https://doi.org/10.1093/ajcn/61.6.1402S.

    Article  CAS  PubMed  Google Scholar 

  33. Dietary Sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet | NEJM. New England Journal of Medicine. https://www-nejm-org.ezproxy.galter.northwestern.edu/doi/10.1056/NEJM200101043440101?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dwww-ncbi-nlm-nih-gov.ezproxy.galter.northwestern.edu. Accessed June 13, 2019.

  34. Sanches Machado d’Almeida K, Ronchi Spillere S, Zuchinali P, Corrêa Souza G. Mediterranean diet and other dietary patterns in primary prevention of heart failure and changes in cardiac function markers: a systematic review. Nutrients. 2018;10(1) https://doi.org/10.3390/nu10010058.

  35. Levitan EB, Wolk A, Mittleman MA. Consistency with the DASH diet and incidence of heart failure. Arch Intern Med. 2009;169(9):851–7. https://doi.org/10.1001/archinternmed.2009.56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Levitan EB, Wolk A, Mittleman MA. Relation of consistency with the dietary approaches to stop hypertension diet and incidence of heart failure in men aged 45 to 79 years. Am J Cardiol. 2009;104(10):1416–20. https://doi.org/10.1016/j.amjcard.2009.06.061.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Lara KM, Levitan EB, Gutierrez OM, et al. Dietary patterns and incident heart failure in U.S. adults without known coronary disease. J Am Coll Cardiol. 2019;73(16):2036–45. https://doi.org/10.1016/j.jacc.2019.01.067.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Contribution of Major Diseases to Disparities in Mortality | NEJM. New England Journal of Medicine. https://www-nejm-org.ezproxy.galter.northwestern.edu/doi/10.1056/NEJMsa012979?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dwww-ncbi-nlm-nih-gov.ezproxy.galter.northwestern.edu. Accessed June 13, 2019.

  39. Chen L, Simonsen N, Liu L. Racial differences of Pediatric hypertension in relation to birth weight and body size in the United States. PLoS One. 2015;10(7):e0132606. https://doi.org/10.1371/journal.pone.0132606.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Carson AP, Howard G, Burke GL, Shea S, Levitan EB, Muntner P. Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis. Hypertension. 2011;57(6):1101–7. https://doi.org/10.1161/HYPERTENSIONAHA.110.168005.

    Article  CAS  PubMed  Google Scholar 

  41. Howard G, Safford MM, Moy CS, et al. Racial differences in the incidence of cardiovascular risk factors in older Black and White adults. J Am Geriatr Soc. 2017;65(1):83–90. https://doi.org/10.1111/jgs.14472.

    Article  PubMed  Google Scholar 

  42. Fuchs FD. Why do black Americans have higher prevalence of hypertension?: an enigma still unsolved. Hypertension. 2011;57(3):379–80. https://doi.org/10.1161/HYPERTENSIONAHA.110.163196.

    Article  CAS  PubMed  Google Scholar 

  43. Howard G, Cushman M, Moy CS, et al. Association of Clinical and Social Factors with Excess Hypertension Risk in Black compared with White US adults. JAMA. 2018;320(13):1338–48. https://doi.org/10.1001/jama.2018.13467.

    Article  PubMed  PubMed Central  Google Scholar 

  44. My Life Check - Life’s Simple 7. http://www.heart.org/HEARTORG/Conditions/My-Life-Check%E2%80%94Lifes-Simple-7_UCM_471453_Article.jsp#.XQFLWNNKgUt. Accessed June 12, 2019.

  45. Aferdita S, Sameera T, Adolfo C, et al. Ideal cardiovascular health, cardiovascular Remodeling, and heart failure in blacks. Circ Heart Fail. 2017;10(2):e003682. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003682.

    Article  Google Scholar 

  46. Casagrande SS, Aviles-Santa L, Corsino L, et al. Hemoglobin A1c, blood pressure, and LDL-cholesterol control among Hispanic/Latino adults with diabetes: results from the Hispanic community health study/study of Latinos (HCHS/SOL). Endocr Pract. 2017;23(10):1232–53. https://doi.org/10.4158/EP171765.OR.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the Management of Heart Failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62(16):1495–539. https://doi.org/10.1016/j.jacc.2013.05.020.

    Article  Google Scholar 

  48. Pandey A, Omar W, Ayers C, et al. Sex and race differences in lifetime risk of heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. Circulation. 2018;137(17):1814–23. https://doi.org/10.1161/CIRCULATIONAHA.117.031622.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Joseph Y, Rodriguez CJ, Brandon S, et al. Prognosis of individuals with asymptomatic left ventricular systolic dysfunction in the multi-ethnic study of atherosclerosis (MESA). Circulation. 2012;126(23):2713–9. https://doi.org/10.1161/CIRCULATIONAHA.112.112201.

    Article  Google Scholar 

  50. Friedman GD, Cutter GR, Donahue RP, et al. Cardia: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol. 1988;41(11):1105–16. https://doi.org/10.1016/0895-4356(88)90080-7.

    Article  CAS  PubMed  Google Scholar 

  51. Bibbins-Domingo K, Pletcher MJ, Lin F, et al. Racial differences in incident heart failure among Young adults. N Engl J Med. 2009;360(12):1179–90. https://doi.org/10.1056/NEJMoa0807265.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Glynn P, Lloyd-Jones DM, Feinstein MJ, Carnethon M, Khan SS. Disparities in cardiovascular mortality related to heart failure in the United States. J Am Coll Cardiol. 2019;73(18):2354–5. https://doi.org/10.1016/j.jacc.2019.02.042.

    Article  PubMed  Google Scholar 

  53. Vivo RP, Krim SR, Krim NR, et al. Care and outcomes of Hispanic patients admitted with heart failure with preserved or reduced ejection fraction. Circ Heart Fail. 2012;5(2):167–75. https://doi.org/10.1161/CIRCHEARTFAILURE.111.963546.

    Article  PubMed  Google Scholar 

  54. Goyal P, Paul T, Almarzooq ZI, et al. Sex- and race-related differences in characteristics and outcomes of hospitalizations for heart failure with preserved ejection fraction. J Am Heart Assoc. 2017;6(4) https://doi.org/10.1161/JAHA.116.003330.

  55. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154(2):260–6. https://doi.org/10.1016/j.ahj.2007.01.041.

    Article  PubMed  Google Scholar 

  56. Reis SE, Holubkov R, Edmundowicz D, et al. Treatment of patients admitted to the hospital with congestive heart failure: specialty-related disparities in practice patterns and outcomes. J Am Coll Cardiol. 1997;30(3):733–8. https://doi.org/10.1016/S0735-1097(97)00214-3.

    Article  CAS  PubMed  Google Scholar 

  57. Harjai KJ, Boulos LM, Smart FW, et al. Effects of caregiver specialty on cost and clinical outcomes following hospitalization for heart failure. Am J Cardiol. 1998;82(1):82–5.

    Article  CAS  PubMed  Google Scholar 

  58. Auerbach AD, Hamel MB, Califf RM, et al. Patient characteristics associated with care by a cardiologist among adults hospitalized with severe congestive heart failure. J Am Coll Cardiol. 2000;36(7):2119–25. https://doi.org/10.1016/S0735-1097(00)01005-6.

    Article  CAS  PubMed  Google Scholar 

  59. Breathett K, Liu WG, Allen LA, et al. African Americans are less likely to receive care by a cardiologist during an intensive care unit admission for heart failure. JACC Heart Failure. 2018;6(5):413–20. https://doi.org/10.1016/j.jchf.2018.02.015.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Joynt KE, Orav EJ, Jha AK. Thirty-day readmission rates for Medicare beneficiaries by race and site of care. JAMA. 2011;305(7):675–81. https://doi.org/10.1001/jama.2011.123.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Burch GE, Walsh JJ, Black WC. Value of prolonged bed rest in Management of Cardiomegaly. JAMA. 1963;183(2):81–7. https://doi.org/10.1001/jama.1963.03700020031008.

    Article  CAS  PubMed  Google Scholar 

  62. Guiha NH, Cohn JN, Mikulic E, Franciosa JA, Limas CJ. Treatment of refractory heart failure with infusion of nitroprusside. N Engl J Med. 1974;291(12):587–92. https://doi.org/10.1056/nejm197409192911201.

    Article  CAS  PubMed  Google Scholar 

  63. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med. 1986;314(24):1547–52. https://doi.org/10.1056/nejm198606123142404.

    Article  CAS  PubMed  Google Scholar 

  64. Ferreira SH. Angiotensin converting enzyme: history and relevance. Semin Perinatol. 2000;24(1):7–10. https://doi.org/10.1016/S0146-0005(00)80046-4.

    Article  CAS  PubMed  Google Scholar 

  65. Lipkin DP, Poole-Wilson PA. Treatment of chronic heart failure: a review of recent drug trials. Br Med J (Clin Res Ed). 1985;291(6501):993–6. https://doi.org/10.1136/bmj.291.6501.993.

    Article  CAS  Google Scholar 

  66. The Consensus Trial Study Group. Effects of Enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316(23):1429–35. https://doi.org/10.1056/nejm198706043162301.

    Article  Google Scholar 

  67. The Consensus Trial Study Group. Effect of Enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302. https://doi.org/10.1056/nejm199108013250501.

    Article  Google Scholar 

  68. The Consensus Trial Study Group. Effect of Enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327(10):685–91. https://doi.org/10.1056/nejm199209033271003.

    Article  Google Scholar 

  69. Cohn JN, Johnson G, Ziesche S, et al. A comparison of Enalapril with hydralazine–isosorbide Dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325(5):303–10. https://doi.org/10.1056/nejm199108013250502.

    Article  CAS  PubMed  Google Scholar 

  70. Julius S, Alderman MH, Beevers G, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the life study. J Am Coll Cardiol. 2004;43(6):1047–55. https://doi.org/10.1016/j.jacc.2003.11.029.

    Article  PubMed  Google Scholar 

  71. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41(9):1529–38. https://doi.org/10.1016/S0735-1097(03)00262-6.

    Article  CAS  PubMed  Google Scholar 

  72. Abraham HMA, White CM, White WB. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Saf. 2015;38(1):33–54. https://doi.org/10.1007/s40264-014-0239-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667–75. https://doi.org/10.1056/NEJMoa010713.

    Article  CAS  PubMed  Google Scholar 

  74. Young JB, Dunlap ME, Pfeffer MA, et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction. Circulation. 2004;110(17):2618–26. https://doi.org/10.1161/01.CIR.0000146819.43235.A9.

    Article  CAS  PubMed  Google Scholar 

  75. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893–906. https://doi.org/10.1056/NEJMoa032292.

    Article  CAS  PubMed  Google Scholar 

  76. Cruden NLM, Fox KAA, Ludlam CA, Johnston NR, Newby DE. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension. 2004;44(6):913–8. https://doi.org/10.1161/01.HYP.0000146483.78994.56.

    Article  CAS  PubMed  Google Scholar 

  77. Wilkinson IB, McEniery CM, Bongaerts KH, MacCallum H, Webb DJ, Cockcroft JR. Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP). Br J Clin Pharmacol. 2001;52(2):159–64. https://doi.org/10.1046/j.0306-5251.2001.1420.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM, Kosoglou T. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin Sci. 1996;91(3):283–91. https://doi.org/10.1042/cs0910283.

    Article  CAS  Google Scholar 

  79. McMurray JJV, Packer M, Desai AS, et al. Angiotensin–Neprilysin inhibition versus Enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077.

    Article  CAS  PubMed  Google Scholar 

  80. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975;37(10):1022–36. https://doi.org/10.1136/hrt.37.10.1022.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Funck-Brentano C. Beta-blockade in CHF: from contraindication to indication. Eur Heart J Suppl. 2006;8(suppl_C):C19–27. https://doi.org/10.1093/eurheartj/sul010.

    Article  CAS  Google Scholar 

  82. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334(21):1349–55. https://doi.org/10.1056/nejm199605233342101.

    Article  CAS  PubMed  Google Scholar 

  83. Drummond GA, Squire IB. The cardiac insufficiency Bisoprolol study II (CIBIS-II): a randomised trial. Lancet (London, England). 1999;353(9146):9–13.

    Article  Google Scholar 

  84. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709–17. https://doi.org/10.1056/nejm199909023411001.

    Article  CAS  PubMed  Google Scholar 

  85. Okwuosa IS, Princewill O, Nwabueze C, et al. The ABCs of managing systolic heart failure: past, present, and future. Cleve Clin J Med. 2016;83(10):753–65. https://doi.org/10.3949/ccjm.83a.16006.

    Article  PubMed  Google Scholar 

  86. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21. https://doi.org/10.1056/NEJMoa1009492.

    Article  CAS  PubMed  Google Scholar 

  87. Gillum RF. Pathophysiology of hypertension in blacks and whites. A review of the basis of racial blood pressure differences. Hypertension (Dallas, Tex: 1979). 1979;1(5):468–75.

    Article  CAS  Google Scholar 

  88. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide Dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049–57. https://doi.org/10.1056/NEJMoa042934.

    Article  CAS  PubMed  Google Scholar 

  89. Saour B, Smith B, Yancy CW. Heart failure and sudden cardiac death. Cardiac Electrophysiol Clin. 2017;9(4):709–23. https://doi.org/10.1016/j.ccep.2017.07.010.

    Article  Google Scholar 

  90. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83. https://doi.org/10.1056/NEJMoa013474.

    Article  PubMed  Google Scholar 

  91. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37. https://doi.org/10.1056/NEJMoa043399.

    Article  CAS  PubMed  Google Scholar 

  92. Hernandez AF, Fonarow GC, Liang L, et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA. 2007;298(13):1525–32. https://doi.org/10.1001/jama.298.13.1525.

    Article  CAS  PubMed  Google Scholar 

  93. Al-Khatib SM, Hellkamp AS, Hernandez AF, et al. Trends in use of implantable cardioverter-defibrillator therapy among patients hospitalized for heart failure: have the previously observed sex and racial disparities changed over time? Circulation. 2012;125(9):1094–101. https://doi.org/10.1161/CIRCULATIONAHA.111.066605.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Hess PL, Hernandez AF, Bhatt DL, et al. Sex and race/ethnicity differences in implantable cardioverter-defibrillator Counseling and use among patients hospitalized with heart failure: findings from the get with the guidelines-heart failure program. Circulation. 2016;134(7):517–26. https://doi.org/10.1161/CIRCULATIONAHA.115.021048.

    Article  PubMed  Google Scholar 

  95. Gordon HS, Paterniti DA, Wray NP. Race and patient refusal of invasive cardiac procedures. J Gen Intern Med. 2004;19(9):962–6. https://doi.org/10.1111/j.1525-1497.2004.30131.x.

    Article  PubMed  Google Scholar 

  96. Thomas KL, Zimmer LO, Dai D, Al-Khatib SM, Allen LaPointe NM, Peterson ED. Educational videos to reduce racial disparities in ICD therapy via innovative designs (VIVID): a randomized clinical trial. Am Heart J. 2013;166(1):157–63. https://doi.org/10.1016/j.ahj.2013.03.031.

    Article  PubMed  Google Scholar 

  97. Alivizatos PA. Fiftieth anniversary of the first heart transplant: the progress of American medical research, the ethical dilemmas, and Christiaan Barnard. Proc (Bayl Univ Med Cent). 2017;30(4):475–7. https://doi.org/10.1080/08998280.2017.11930236.

    Article  Google Scholar 

  98. Silbergleit A, Norman E. Shumway and the early heart transplants. Tex Heart Inst J. 2006;33(2):274–5.

    PubMed  PubMed Central  Google Scholar 

  99. Borel JF, Kis ZL, Beveridge T. The history of the discovery and development of cyclosporine (Sandimmune®). In: Merluzzi VJ, Adams J, editors. The search for anti-inflammatory drugs: case histories from concept to clinic. Boston: Birkhäuser Boston; 1995. p. 27–63. https://doi.org/10.1007/978-1-4615-9846-6_2.

    Chapter  Google Scholar 

  100. Sivathasan C. Experience with cyclosporine in heart transplantation. Transplant Proc. 2004;36(2, Supplement):S346–8. https://doi.org/10.1016/j.transproceed.2004.01.072.

    Article  CAS  Google Scholar 

  101. Alraies MC, Eckman P. Adult heart transplant: indications and outcomes. J Thorac Dis. 2014;6(8):1120–8. https://doi.org/10.3978/j.issn.2072-1439.2014.06.44.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Singh Tajinder P, Almond Christopher S, Taylor David O, Milliren Carly E, Graham DA. Racial and ethnic differences in wait-list outcomes in patients listed for heart transplantation in the United States. Circulation. 2012;125(24):3022–30. https://doi.org/10.1161/CIRCULATIONAHA.112.092643.

    Article  CAS  PubMed  Google Scholar 

  103. Allen JG, Weiss ES, Arnaoutakis GJ, et al. The impact of race on survival after heart transplantation: an analysis of more than 20,000 patients. Ann Thorac Surg. 2010;89(6):1956–64. https://doi.org/10.1016/j.athoracsur.2010.02.093.

    Article  PubMed  Google Scholar 

  104. Suryanarayana PG, Copeland H, Friedman M, Copeland JG. Cardiac transplantation in African Americans: a single-Center experience. Clin Cardiol. 2014;37(6):331–6. https://doi.org/10.1002/clc.22275.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Kilic A, Conte JV, Shah AS, Yuh DD. Orthotopic heart transplantation in patients with metabolic risk factors. Ann Thorac Surg. 2012;93(3):718–24. https://doi.org/10.1016/j.athoracsur.2011.11.054.

    Article  PubMed  Google Scholar 

  106. Kilic A, Higgins Robert SD, Whitson Bryan A, Kilic A. Racial disparities in outcomes of adult heart transplantation. Circulation. 2015;131(10):882–9. https://doi.org/10.1161/CIRCULATIONAHA.114.011676.

    Article  PubMed  Google Scholar 

  107. DuBay DA, MacLennan PA, Reed RD, et al. Insurance type and solid organ transplantation outcomes: a historical perspective on how Medicaid expansion might impact transplantation outcomes. J Am Coll Surg. 2016;223(4):611–620.e4. https://doi.org/10.1016/j.jamcollsurg.2016.07.004.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Emani S, Tumin D, Foraker RE, Hayes D Jr, Smith SA. Impact of insurance status on heart transplant wait-list mortality for patients with left ventricular assist devices. Clin Transplant. 2017;31(2) https://doi.org/10.1111/ctr.12875.

  109. Prinzing A, Herold U, Berkefeld A, Krane M, Lange R, Voss B. Left ventricular assist devices-current state and perspectives. J Thorac Dis. 2016;8(8):E660–6. https://doi.org/10.21037/jtd.2016.07.13.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435–43. https://doi.org/10.1056/NEJMoa012175.

    Article  CAS  PubMed  Google Scholar 

  111. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361(23):2241–51. https://doi.org/10.1056/NEJMoa0909938.

    Article  CAS  PubMed  Google Scholar 

  112. Kirklin JK, Naftel DC, Pagani FD, et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant. 2015;34(12):1495–504. https://doi.org/10.1016/j.healun.2015.10.003.

    Article  PubMed  Google Scholar 

  113. Breathett K, Allen Larry A, Helmkamp L, et al. Temporal trends in contemporary use of ventricular assist devices by race and ethnicity. Circ Heart Fail. 2018;11(8):e005008. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005008.

    Article  PubMed  PubMed Central  Google Scholar 

  114. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288(5789):373–6.

    Article  CAS  PubMed  Google Scholar 

  115. Stuart-Smith K. Demystified. Nitric oxide. Mol Pathol. 2002;55(6):360–6. https://doi.org/10.1136/mp.55.6.360.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987;84(24):9265–9. https://doi.org/10.1073/pnas.84.24.9265.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Mata-Greenwood E, Chen D-B. Racial differences in nitric oxide-dependent vasorelaxation. Reprod Sci. 2008;15(1):9–25. https://doi.org/10.1177/1933719107312160.

    Article  CAS  PubMed  Google Scholar 

  118. Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 1(2):e000364. https://doi.org/10.1161/JAHA.111.000364.

  119. Vieira M, Saraiva MJ. Transthyretin: a multifaceted protein. BMC. 2014;5(1):45. https://doi.org/10.1515/bmc-2013-0038.

    Article  CAS  Google Scholar 

  120. Colon W, Kelly JW. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry. 1992;31(36):8654–60. https://doi.org/10.1021/bi00151a036.

    Article  CAS  PubMed  Google Scholar 

  121. Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in Black Americans. N Engl J Med. 1997;336(7):466–73. https://doi.org/10.1056/nejm199702133360703.

    Article  CAS  PubMed  Google Scholar 

  122. Yancy CW, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776–803.

    Article  PubMed  Google Scholar 

  123. Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016;68(12):1323–41.

    Article  PubMed  Google Scholar 

  124. Ruberg FL, et al. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA

    Quentin R. Youmans, Ike S. Okwuosa & Clyde W. Yancy

Authors
  1. Quentin R. Youmans
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ike S. Okwuosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Clyde W. Yancy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Clyde W. Yancy .

Editor information

Editors and Affiliations

  1. Tulane University School of Medicine, New Orleans, LA, USA

    Keith C. Ferdinand

  2. Cardiovascular Research Institute, Morehouse School of Medicine, Atlanta, GA, USA

    Herman A. Taylor, Jr.

  3. School of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA

    Carlos J. Rodriguez

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Youmans, Q.R., Okwuosa, I.S., Yancy, C.W. (2021). Heart Failure in African Americans and Hispanic Americans: A Persistent and Disproportionate Burden in Underrepresented Minorities. In: Ferdinand, K.C., Taylor, Jr., H.A., Rodriguez, C.J. (eds) Cardiovascular Disease in Racial and Ethnic Minority Populations. Contemporary Cardiology. Humana, Cham. https://doi.org/10.1007/978-3-030-81034-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-81034-4_7

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-81033-7

  • Online ISBN: 978-3-030-81034-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation